A RANDOMIZED PROSPECTIVE CONTROLLED TRIAL OF ORAL ACYCLOVIR VERSUS ORAL GANCICLOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS1
Distribution of the number of citations over years.